TORONTO and RIONEGRO, Colombia, June 23, 2021 / CNW / – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent company of Colombia PharmaCielo Colombia Holdings SAS, the leading breeder and manufacturer of medical-grade cannabis extracts, announced today that Henning von Koss, Chief Executive Officer will participate in a discussion at the Cantor Fitzgerald International Cannabis Forum on. take part June 28, 2021.
Date: Monday, June 28, 2021.
Time: 12:00 PM ET
To register: https://us06web.zoom.us/webinar/register/WN_HMS7kf5zQEOpc1drtylmzA
For additional information or to arrange a face-to-face meeting with management, please contact your conference representative or the company’s investor relations team at [email protected].
PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company based in Canada, with an emphasis on ethical and sustainable processing and delivery of all natural medical grade cannabis oil extracts and related products to large distribution channels. PharmaCielo’s main (and wholly owned) subsidiary is PharmaCielo Colombia Holdings SAS, headquartered in its cultivation and processing center in Rionegro, Colombia.
PharmaCielo’s board of directors and management team consists of a diverse, talented group of international executives and specialists with relevant and diverse expertise. PharmaCielo has recognized the significant role that Colombia ideal location and climatic conditions for building a sustainable business in the medical cannabis industry, and the company, together with its directors and executives, is implementing a business plan geared towards serving the international market.
This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”). These forward-looking statements relate to future events or the future performance of the company. All statements that are not historical facts are forward-looking statements. In particular, information about our expectations with respect to future results, goals, performance, prospects or opportunities is forward-looking information.
Forward-looking statements are based on assumptions made by management at the time the forward-looking statements were made, including assumptions about: the company’s ability to execute its business plan, including the growth of its global sales team as currently planned; the company’s ability to obtain the necessary regulatory, regulatory and TSXV clearances to export its products from Colombia and importing its products to other countries; there is sufficient demand for the company’s products; that the company’s development plans will not change due to unforeseen events; that the company’s business in general and shipping logistics are not disrupted by COVID 19 or other factors; that the company will be able to keep its customer contracts in good shape; that the Company will be able to obtain GMP and EU GMP certification for the Company’s Processing and Extraction Center (“PEC”); that potential customers are satisfied with the results of the audit processes; that changes in Colombian cannabis legislation will not adversely affect the company’s business; that the company will be able to find and retain the necessary staff to achieve its business objectives; the company’s ability to keep its distribution agreements in good working order; and the accuracy of the Company’s predictions regarding the Cannabinoid Products market; Exchange rates; and competition in the company’s markets.
Although management believes that its assumptions are reasonable under the given circumstances, forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements of the company to materialize by all or some future results, performance, or achievements expressed or implied by forward-looking statements. Factors that could cause actual results, performance, or achievements of the company to differ from the forward-looking statements include, but are not limited to, the risk that: any of the above assumptions will prove to be invalid or reliable and additional risks that may arise Described in the company’s annual information form for the past year December 31, 2019 Filed with the Canadian Securities and Exchange Commission under the company’s SEDAR profile at www.sedar.com. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements.
Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE PharmaCielo Ltd.
For further information: Henning von Koss, CEO, +1 416-864-6116, PharmaCielo.com; Media Relations: International: Gal Wilder, Cohn & Wolfe, +1 416-602-4092, [email protected]; Colombia: Giselle Díaz Bermúdez, SPR Group, + 57 310 859 5468, [email protected]; Investor inquiries: [email protected]